Plain-English translation of NCT07523555 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new approach called dual-target CAR-T cell therapy for people with blood cancers that have returned or stopped responding to previous treatments. Researchers take some of your own immune cells, engineer them in the lab to recognize and fight cancer cells from two different angles at once, and then put them back into your body. The idea is that by targeting cancer from two directions simultaneously, the treatment might work better and prevent the cancer from escaping.
Many patients whose blood cancers return after CAR-T cell therapy develop resistance because cancer cells can hide by turning off one of the markers that the treatment was designed to recognize. This trial was created to test whether targeting two markers at the same time could prevent that escape route and help more patients achieve lasting remission.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will first test your cancer cells to see which engineered cells would work best for you. You'll then undergo a procedure called leukapheresis, where your immune cells are collected from your blood. After a short course of chemotherapy to prepare your body, you'll receive an infusion of your engineered cells on Day 0. You'll be closely monitored in the hospital or clinic for at least the first 28 days, then return for regular follow-up visits through 2 years, with some participants followed for up to 15 years to track long-term safety.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China